ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / LSTA / financials
GTBP (36) GDTC (52) ASBP (40) CLRB (32) ⌘ Pro Terminal →

Lisata Therapeutics Inc. (LSTA) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.01 -0.98% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.01

Lisata Therapeutics Inc. (LSTA) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $11.0M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LSTA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LSTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Lisata Therapeutics Inc. (NASDAQ: LSTA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $1.01 (-0.98% 1D, market cap $11.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, LSTA ranks #848 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LSTA compare to GTBP and GDTC in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LSTA carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GTBP (GT Biopharma Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $11.0M) and GDTC (CytoMed Therapeutics Limited) posts a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $10.9M). Among the 5-stock peer group, LSTA leads on earnings multiple (N/A) while LSTA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LSTA?
▼

Per LSTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000320017), Lisata Therapeutics Inc. generated $170.0K in revenue (-83.0% YoY), -$17.0M in net income, and -$16.0M in free cash flow against $17.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.01 (-0.37%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510029
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (8)Whales (3)SEC (8)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.9% Base Target
$5 Bull$1 Base$1 Bear
📬 FREE LSTA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LSTA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (29/100 Composite)
🔍 WHY LSTA SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+8/20 pts (28% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
37
Grade E$1.08-3.7% Next Q
Q2 (-2Q)
34
Grade E$1.04-1.9% Next Q
Q3 (-1Q)
32
Grade E$1.02-1% Next Q
Current
29
Grade E$1.01-9.8% Hist 90D α
Trajectory: E (37) → E (29)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LSTA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LSTA currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.37) and Max Pain ($1.06) forces dealer call-delta covering toward $5.32.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LSTA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LSTA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 29%NO 71%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How LSTA Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)
Revenue$1.0MGross Profit $520.0K (52%)Cost of Sales $480.0KOp Profit $0 (0%)OpEx (R&D/SG&A) $520.0KNet Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow
FY23
Rev $72.0M
FY24
Rev $1.0M
FY25
Rev $170.0K
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$170.0K52%-80%-$17.0M-$16.0M-45%
FY 2024$1.0M52%-80%-$20.0M-$19.4M-45%
FY 2023$72.0M52%-35.7%-$21.0M-$20.0M-35%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LSTA)

  • ✓Walkthrough of LSTA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
LSTA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -69.85%🛡️ HOLDING TREND SUPPORT
2026-11-03O $1.01H $1.02L $1.01C $1.01VOL 60.8K
RES: $1.62SUP: $0.96SMA50: $1.37SMA200: $2.98
$4.62$3.63$2.64$1.64$0.65RES $1.62SUP $0.96$1.012026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LSTA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LSTA Butterfly Map → + Track LSTA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -83.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on LSTA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LSTA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LSTA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LSTA)

Health Care Rank #848 of 1015 ⚔️ GTBP vs LSTA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LSTA vs. GTBP, GDTC, ASBP, CLRB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Lisata Therapeutics Inc. (LSTA) ranks #848 by composite RQD confidence (29/100, grade E) and #884 by equity capitalization ($11.0M). Within this direct 5-issuer industry benchmark cohort, LSTA leads on earnings valuation at N/A trailing P/E, while LSTA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GDTC currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with LSTA at 29/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
LSTA ACTIVE
Lisata Therapeutics Inc.
E 29/100 — — -35.0% -0.98% $11.0M Benchmark Subject
GTBP
GT Biopharma Inc.
D- 36/100 — — -35.0% -3.57% $11.0M /gtbp-vs-lsta →
GDTC
CytoMed Therapeutics Limited
D+ 52/100 — — — -0.98% $10.9M /gdtc-vs-lsta →
ASBP
Aspire-Lakewood Holdings Inc.
D- 40/100 — -1.9% -35.0% -9.99% $11.4M /asbp-vs-lsta →
CLRB
Cellectar Biosciences Inc.
E 32/100 — — -35.0% +1.25% $11.4M /clrb-vs-lsta →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000320017 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lisata Therapeutics Inc. (LSTA) reported GAAP revenue of $170.0K (-83.0% vs. FY2024 revenue of $1.0M , and -99.8% cumulative change since FY2023) , GAAP net income of -$17.0M, operating cash flow of -$15.9M, and free cash flow of -$16.0M (+17.5% YoY). On the balance sheet, LSTA closed FY2025 with $17.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $170.0K -$17.0M -$15.9M -$16.0M $17.7M —
FY2024 (FY) 2024-12-31 $1.0M -$20.0M -$19.4M -$19.4M $35.0M —
FY2023 (FY) 2023-12-31 $72.0M -$21.0M -$20.0M -$20.0M — —

3. LSTA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LSTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Lisata Therapeutics Inc. (NASDAQ: LSTA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $1.01 (-0.98% 1D, market cap $11.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, LSTA ranks #848 in composite RQD confidence.

How does LSTA compare to GTBP and GDTC in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LSTA carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GTBP (GT Biopharma Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $11.0M) and GDTC (CytoMed Therapeutics Limited) posts a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $10.9M). Among the 5-stock peer group, LSTA leads on earnings multiple (N/A) while LSTA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LSTA?

Per LSTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000320017), Lisata Therapeutics Inc. generated $170.0K in revenue (-83.0% YoY), -$17.0M in net income, and -$16.0M in free cash flow against $17.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LSTA trading relative to its 50-day, 200-day, and 52-week technical levels?

LSTA last traded at $1.01 (-0.98% on volume of 97,152 shares), positioning the stock -26.28% below its 50-day simple moving average ($1.37) and -66.11% below its 200-day simple moving average ($2.98). Across its 52-week range of $0.96 to $5.07, LSTA sits at the 1.2% percentile with a 14-day RSI of 39.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.14).

Direct Sub-Reports: LSTA RQD Cockpit LSTA 12M Forecast LSTA Earnings & Move LSTA Dividends & DRIP LSTA Insiders & 13F LSTA Whale Options LSTA Profit Sankey LSTA News & Why
ROARABLE RATING BRIEF • RQD 29/100 (E) ✓ SEC XBRL & RQD VERIFIED

LSTA — Lisata Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Lisata Therapeutics Inc. (LSTA) earns a live Roarable RQD composite score of 29/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.01 (-0.98% 1D, market capitalization $11.0M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Lisata Therapeutics Inc. (LSTA) is a NASDAQ-listed operating company in the Biotechnology: Pharmaceutical Preparations industry (Health Care sector) with an equity market capitalization of $11.0M. The business operates with a gross margin of 0%, an operating margin of -60%, and a return on invested capital (ROIC) of -35% (free cash flow yield of 0%). Within the Biotechnology: Pharmaceutical Preparations peer group, investor evaluation centers on operating leverage, unit margin durability, and capital allocation efficiency across market cycles.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Lisata Therapeutics Inc. (LSTA) reported $170.0K in annual revenue (up from $1.0M in FY2024, -83.0% YoY) and -$17.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($72.0M revenue, -$21.0M net income) through FY2025, LSTA scaled operating cash flow to -$15.9M and free cash flow to -$16.0M, backed by $17.7M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 29/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.96 – $5.07 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— Upstream and downstream dependencies, sector correlations beyond the stated beta of 1.0, and second-order bottlenecks cannot be determined from the source data.

  • Key Question #1: Can LSTA sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $170.0K and free cash flow of -$16.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is LSTA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

LSTA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Lisata Therapeutics Inc. (LSTA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LSTA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LSTA Bull vs. Bear Conversation Board — What's Your Call at $1.01?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LSTA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on LSTA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $1.17 (+14.7%)
📌 Pinned Debate

A newly reported US patent for a pancreatic cancer drug is the only positive catalyst in the news wire.

A newly reported US patent for a pancreatic cancer drug is the only positive catalyst in the news wire.. When you look under the hood at LSTA, Fundamental Cash Engine is 8/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $5.07. My 12M target is $1.17.

EarningsSniper 🐂 BULL

@ForensicBear Shorting a 3/20 institutional whale-flow stock at $1.02 is dangerous when funds are rotating into Health Care.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $0.77 (-24.5%)
Spot @ $1.02

A 29/E RQD score with 0% FCF yield and -35% ROIC, against FY 2025 cash of $16.0M versus FCF of -$16.0M, signals limited runway and fore

Here is the bear case nobody on the bull side wants to address on LSTA: A 29/E RQD score with 0% FCF yield and -35% ROIC, against FY 2025 cash of $16.0M versus FCF of -$16.0M, signals limited runway and forensic risk.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%